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ABSTRACT 
 
Background 
As the outbreak of coronavirus disease 2019 (COVID-19) progresses, prognostic 
markers for early identification of high-risk individuals are an urgent medical need. Italy 
has the highest rate of SARS-CoV-2 infection, the highest number of deaths, and the 
highest mortality rate among large countries. Worldwide, a more severe course of 
COVID-19 is associated with older age, comorbidities, and male sex. Hence, we 
searched for possible genetic components of the peculiar severity of COVID-19 
among Italians, by looking at expression levels and variants in ACE2 and TMPRSS2 
genes, which are crucial for viral infection. 
 
Methods 
Exome and SNP array data from a large Italian cohort representative of the 
country’s population were used to compare the burden of rare variants and the 
frequency of polymorphisms with European and East Asian populations. Moreover, 
we looked into gene expression databases to check for sex-unbalanced expression. 
 
Results 
While we found no significant evidence that ACE2 is associated with disease 
severity/sex bias in the Italian population, TMPRSS2 levels and genetic variants 
proved to be possible candidate disease modulators, contributing to the observed 
epidemiological data among Italian patients. 
 
Conclusions 
Our analysis suggests a role for TMPRSS2 variants and expression levels in 
modulating COVID-19 severity, a hypothesis that fosters a rapid experimental 
validation on large cohorts of patients with different clinical manifestations. 
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INTRODUCTION 
 
As we write, Italy, Europe, and the entire world are facing one of the worst medical 
emergencies spanning centuries, the coronavirus disease 2019 (COVID-19) 
pandemia due to infection by SARS-CoV-2 virus. The early identification of risk factors 
for COVID-19 is an urgent medical need to provide the appropriate support to patients, 
including access to intensive care units. 
Presently, Italy has one of the highest rate of SARS-CoV-2 infection in the world 
among large countries, with 143 cases per 100,000 people, the highest number of 
deaths and the highest mortality rate, 10.5% vs. an average value of 4.6% (as of March 
28th, 2020, data from https://coronavirus.jhu.edu/map.html). These data may have 
different explanations, including: 1) the number of tests performed, 2) the structure of 
the population (Italy has the oldest population in Europe) 
[https://ec.europa.eu/eurostat/data/database], 3) the percentage of smokers, even 
though no significant association was found between smoking and severity of COVID-
19 in a very recent study on the Chinese population,1 4) the possible existence of a 
different virus strain,2 5) the concentration of severe cases in a limited region of the 
country, potentially overwhelming the available intensive care units, as well as 6) 
differences in environmental factors (e.g. air pollution). However, there could also be 
some peculiar genetic characteristics of the Italian population that may have an impact 
on the susceptibility to viral infection, the disease severity, and the number of patients 
shedding huge amounts of virus. 
What is unquestionable is a more severe course of the disease associated with older 
age and high number of comorbidities and with the male sex (male:female ratio in case 
fatality rate among Italians 1.75, data from the Italian National Institute of Health: 
https://www.epicentro.iss.it/coronavirus/), a feature shared with the 2003 SARS 
epidemic and MERS.3-5 Indeed, while men and women have similar susceptibility to 
both SARS-CoV-2 and SARS-CoV, men are more prone to have higher severity and 
mortality, independently of age.3 Among the many possible factors impacting on sex-
related differences in disease manifestations, including the fact that females are 
known to mount a stronger immune response to viral infections compared to males 
due to more robust humoral and cellular immune responses,6 we decided to center 
our attention on possible genetic components, with a particular focus on the Italian 
population. 
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It was recently demonstrated that both angiotensin I converting enzyme 2 (ACE2) and 
the transmembrane protease, serine 2 (TMPRSS2) are crucial for SARS-CoV-2 entry 
into host cells.7,8 While ACE2 is the main receptor for the spike (S) protein of both 
SARS-CoV and SARS-CoV-2, mediating viral attachment to target cells, TMPRSS2 
cleaves protein S at the S1/S2 and the S2 ’sites, allowing fusion of viral and cellular 
membranes.8 Both genes have been proposed to modulate susceptibility to SARS-
CoV,9,10 and are good candidates to mediate sex-related effects: ACE2 is located on 
the X chromosome, while TMPRSS2 expression is responsive to androgen/estrogen 
stimulation.11 
 
METHODS 
 
Gene expression data 
Expression data for ACE and TMPRSS2 genes were obtained through the: 1) 
genotype-tissue expression (GTEx) database (https://gtexportal.org/home/), which 
was also used to extract quantitative trait loci (eQTLs) for the two genes (all data based 
on RNAseq experiments); and 2) Gene Expression Omnibus (GEO) repository 
(https://www.ncbi.nlm.nih.gov/geo/). In particular, two GEO datasets were extracted 
and analyzed: 1) GSE66499, reporting microarray data on 152 normal lung samples 
from Caucasian individuals; 2) GSE19804, reporting microarray data on 60 normal 
lung samples from Taiwanese females. 
 
Genetic data 
Genetic data for general European and East Asian populations were retrieved through 
the GnomAD repository, which contains data on a total of 125,748 exomes and 71,702 
genomes (https://gnomad.broadinstitute.org/). 
As for Italians, details on whole-exome sequencing (on 3,984 individuals) and 
genome-wide microarray genotyping (on 3,284 individuals) of the analyzed cohort are 
specified elsewhere.12-14 Imputation procedures are detailed in Supplementary 
materials. 
 
Statistical analysis 
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Expression levels were compared by using either the Kruskal-Wallis test (RNAseq 
data) or the student t test (microarray data). Allele frequencies were compared using 
the chi square test. All calculations were performed using the R software 
(https://www.r-project.org/). P values are presented as non-corrected for multiple 
testing. 
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RESULTS AND DISCUSSION 
 
ACE2 
For most X-chromosome genes, the double allelic dosage in women is balanced by 
the epigenetic silencing of one of the X chromosomes in early development.15 
However, the X-chromosome inactivation (XCI) is incomplete in humans and up to one 
third of genes are expressed from both alleles, with the degree of XCI escape varying 
between genes and individuals.16 ACE2 is one of the genes escaping X inactivation, 
but it belongs to a subgroup of X-chromosome genes escaping XCI showing an 
uncharacteristically heterogeneous pattern of male-female expression, with higher 
expression in men in several tissues.17 Specifically concerning the lung, a recent 
analysis on published expression data, reported a substantial similar level of ACE2 
transcript in men and women,18 however, another study, using single-cell sequencing, 
found a higher expression of ACE2 in Asian men.19 Supplementary Figure 1 reports 
data on ACE2 mRNA expression levels in the lung as retrieved from the largest 
datasets available in the literature; no substantial differences were found between 
males and females, nor between younger and older women, thus confirming what 
already observed by Cai and colleagues.18 
Another possible sex-related effect might be due to the fact that males are hemizygous 
for the gene, therefore, in the presence of an ACE2 allelic variant increasing disease 
susceptibility or severity, men will have all cells expressing the risk variant. Based on 
this hypothesis, we looked into the genetic variation in ACE2. A recent manuscript 
explored this same topic in different populations using data from public databases. 20 
However, a specific analysis of the Italian population is Iacking. 
We have therefore exploited the available data on 3,984 exomes obtained from an 
Italian cohort representative of the whole country12,13 to extract the variants in exons 
and splice junctions of ACE2. Variants were filtered for quality and classified according 
to their predicted effect at protein level and on splicing. Concerning rare variants (i.e. 
those with a minor allele frequency, MAF, <1%; to be used in burden tests), we 
considered only null variants, abolishing or significantly impairing protein production 
(nonsense, out-of-frame ins/dels, and splicing variants), and missense variants 
predicted to be deleterious or possibly deleterious by all the 5 prediction algorithms 
used (see Supplementary Methods). Concerning common variants (i.e., MAF>5%), all 
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were retained for comparing their frequency with those of the European (non Finnish) 
and East Asian populations, retrieved from the GnomAD repository. 
No significant differences in the burden of rare deleterious variants were observed 
comparing the Italian population with Europeans and East Asians (Table 1A). 
Concerning common exonic variants, the only striking difference, as also noticed by 
Cao and colleagues,20 was observed for the single nucleotide polymorphism (SNP) 
rs2285666 (also called G8790A), with the frequency of the rare A allele being 0.2 in 
Italians and Europeans, and 0.55 in East Asians (P=2.2*10-16 for difference in Italians 
vs East Asians; Table 1B). This variant was extensively studied as a potential risk 
factor for hypertension, type 2 diabetes, and coronary artery disease,21,22 hence 
possibly constituting a predisposing factor also for the comorbidities observed in 
COVID-19 patients. A single paper reports the association of the three rs2285666 
genotypes with ACE2 protein level measured in serum by ELISA, with the A/A 
genotype having an expression level almost 50% lower than the G/G genotype.23 
Given the position of the variant, at nucleotide +4 in the donor splice site of intron 3 
(c.439+4G>A), we calculated the predicted effect on splicing and indeed the 
substitution of G with an A is predicted to increase the strength of the splice site of 
about 9.2% (calculation made through the Human Splicing Finder v.3.1 webtool, 
http://www.umd.be/HSF/), not consistently with the higher level of ACE2 protein in 
serum. Hence, it would be crucial to compare the frequency of this variant with ACE2 
expression in the lung and with susceptibility to viral infection and severity of COVID-
19 manifestations. Of note, no eQTL for ACE2 in the lung has been described so far 
in the GTEx database, and investigations on this topic are recommended. 
 
TMPRSS2 
Our second candidate is TMPRSS2. This gene is well known to oncologists as genetic 
rearrangements producing a fusion between TMPRSS2 and ERG (or, more rarely, 
other members of the ETS family) are the most frequent genetic lesions in prostate 
cancer patients.24 As TMPRSS2 is an androgen responsive gene, the fusion results in 
androgen dependent transcription of ERG in prostate tumor cells. Therefore, we can 
hypothesize that men might have higher TMPRSS2 expression also in the lung, which 
might improve the ability of SARS-CoV-2 to enter cells by promoting membrane fusion. 
Looking into GTEx and GEO data , the overall expression of TMPRSS2 in the lung is 
only slightly increased in men (P=0.029; Figure 1A). However, TMPRSS2 expression 
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is also promoted by estrogens,11 and therefore the situation might be different when 
considering individuals above 60 years, who are at higher risk of fatal events due to 
COVID-19, as in this group women will all be postmenopausal. According to this 
hypothesis, we checked the expression of the gene in lungs of men and females at 
different ages, but no substantial differences emerged between males and females 
(neither below, nor above 60 years of age; data not shown). 
Finally, we explored genetic variation in TMPRSS2 in search of variants, possibly 
already annotated as eQTL in the lung, which might have an impact on the serine 
protease expression as well as on its catalytic activity. Again, we used the available 
Italian exome data, as well as data deposited in GnomAD.25 
Firstly, we looked at the overall burden of deleterious rare variants, using the variant 
classification described above. Italians had a significant decrease in the burden of 
deleterious variants compared to Europeans (P=0.039; Table 2A) suggesting that they 
might have a higher level of TMPRSS2 protein/activity, which in principle should be a 
risk factor for more severe disease course. This is even more true for the East Asian 
population, however, in this case, we must consider that the number of individuals 
over 65 years of age in Italy is more than double the one in the Hubei province (22.7 
vs. 10%, respectively) and this is a major determinant of disease lethality. 
Focusing specifically on common exonic variants, 4 SNPs showed significantly 
(P<2.2*10-16) different frequencies when comparing the Italian population with East 
Asians (and with Europeans) (Table 2B); 3 of them are synonymous variants, whereas 
one is the missense substitution p.Val160Met, which impacts on a residue far from the 
serine protease catalytic triad. This variant was previously found significantly 
associated with genomic rearrangements involving TMPRSS2, with the risk of prostate 
cancer26 and with shorter time to prostate cancer diagnosis for high-risk patients.27 
Concerning eQTLs, a number of variants significantly impacting on TMPRSS2 
expression in the lung (GTex data) are reported in the 3’ region of the gene (Figure 
1B). In Table 2C, a list of the most significant (P<1*10-8), together with their GnomAD 
frequencies in the East Asian and European populations, are reported. As for the 
Italian frequencies, we took advantage of the genome-wide association study (GWAS) 
performed on the above-described cohort (for a total of 3,284 individuals);14 in this 
case, we had to infer genotype frequencies by an imputation approach (for details, see 
Supplementary Methods). Interestingly, all these eQTLs appear to have extremely 
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different frequencies among populations. In particular, 2 different haplotypes can be 
inferred from frequency data: 
1) A frequent “European” haplotype (composed at least of SNPs rs463727, 
rs34624090, rs55964536, rs734056, rs4290734, rs34783969, rs11702475, 
rs35899679, and rs35041537), which is totally absent in the Asian population. 
Interestingly, this haplotype has been functionally linked to another eQTL (rs8134378), 
located at a known androgen-responsive enhancer for TMPRSS2, 13 kb upstream of 
the TMPRSS2 transcription start site28 (Figure 1B). Hence, this haplotype is expected 
to up regulate TMPRSS2 gene expression in an androgen-specific way. 
2) A second haplotype, predicted to be associated with higher TMPRSS2 expression, 
is characterized by 3 SNPs (rs2070788, rs9974589, rs7364083), whose MAF is 
significantly increased in Europeans (9% increase in Italians respect to East Asians, 
P<1.9*10-10). Importantly, a small-scale GWAS, comparing the distribution of genetic 
variants in severe and mild cases of patients with A(H1N1)pdm09 influenza, identified 
rs2070788 as being associated with increased risk to both human A(H7N9) and severe 
A(H1N1)pdm09 influenza.10 Of note, also in A(H7N9) influenza, the proportion of male 
patients was more than double that of female patients.29 
 
Limitations and conclusions 
We are aware of the limitations of our study: first of all we focused our attention only 
to two candidate genes identified on the basis of their crucial role in viral infection and 
on the a priori probability that they might mediate sex-specific effects. A number of 
other X-linked genes (such as IL13, IL4, IL10, XIST, TLR7, FOXP3) and Y-linked 
genes (SRY, SOX9) may underlie sexually dimorphic immune responses.30 Moreover, 
the number of non-genetic determinants of sex-biased severity and case fatality rates 
is huge and probably has to do not only with sex differences in both innate and 
adaptive immune responses,6 but also with gender and cultural habits in different 
countries. 
In conclusion, we have explored possible genetic components impacting on the sex-
biased severity of COVID-19, focusing on effects mediated by ACE2 and TMPRSS2 
genes in the Italian population. From available data, it seems unlikely that sex-
differences in ACE2 levels can explain sex differences in disease severity. However, 
it remains to be evaluated if changes in ACE2 levels in the lung correlate with 
susceptibility and severity of SARS-CoV-2 infection. Experimental data from patients 
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with different disease manifestations are urgently needed. Among the analyzed 
hypotheses, the most interesting signals refer to sex-related differences in TMPRSS2 
expression and in genetic variation in TMPRSS2. In particular, we identified an exonic 
variant (p.Val160Met) and 2 distinct haplotypes showing profound frequency 
differences between East Asians and Italians. The rare alleles of these haplotypes, all 
predicted to induce higher levels of TMPRSS2, are more frequent in the Italian than in 
the East Asian population; in one case, the haplotype could be regulated through 
androgens (possibly explaining the sex bias in COVID-19 severity?), in the other case, 
a SNP belonging to the haplotype has been associated with increased susceptibility 
to influenza, possibly related to a higher susceptibility in Italians and Europeans. 
Our data, beside suggesting possible explanations for the unusually high, relative to 
known data, lethality rates among Italians, provide reference frequencies in the 
general Italian population for candidate variants that can be compared to genetic data 
from patients infected by SARS-CoV-2 with different disease manifestations, as soon 
as they will be available on large numbers of patients. These studies will hopefully 
help to identify useful prognostic markers to stratify patients and provide the best care 
to high-risk individuals. 
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FIGURE  
 
Figure 1: TMPRSS2 expression levels and eQTLs 
A) Both panels show TMPRSS2 mRNA expression levels in human normal lung 
samples stratified according to sex. On the left, data were retrieved for a total of 578 
RNAseq experiments from the GTex repository. Expression levels are reported as 
transcripts per kilobase million (TPM). On the right, data were collected for a total of 
170 microarray experiments from the GEO database. Expression levels are reported 
as normalized signal intensities. P values were calculated by using either the Kruskal-
Wallis or the student t test. 
 15 
B) Screenshot from the UCSC Genome browser (http://genome.ucsc.edu/; 
GRCh37/hg19) highlighting the TMPRSS2 region (coordinates chr21: 42,835,000-
42,905,000). The panel shows the following tracks: i) the ruler with the scale at the 
genomic level; ii) chromosome 21 nucleotide numbering; iii) the UCSC RefSeq track; 
iv) enhancers (grey and red bars) from GeneHancer database; v) interactions (curved 
lines) connecting GeneHancer regulatory elements and genes: all curved lines 
converge towards the androgen-responsive enhancer for the TMPRSS2 gene 
described by Clinckemalie and colleagues.28 
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Table 1A. Burden of rare mutations in the ACE2 gene in different populations. 
 
Population N alleles T1 Freq T1 ITA EUR EAS 
ITA 4422 7 0.0016 - P=0.518 P=0.974 
EUR 92545 200 0.0022 P=0.518 - P=0.077 
EAS 14840 21 0.0014 P=0.974 P=0.077 - 
 
Total allele counts, carrier allele counts, and carrier frequencies are shown; only deleterious 
variants with MAF less than 1% were considered in the burden analysis. The ‘deleterious’ set 
is defined by missense variations predicted to be possibly damaging by all the 5 algorithms 
used (LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar, and SIFT), and 
loss-of-function variants (nonsense, frameshift, and splicing variants affecting the 
donor/acceptor sites).  
T1: alleles carrying damaging variants; Freq T1: frequency of T1 allele; ITA: Italian population; 
EUR: European population; EAS: East Asian population 
 17 
Table 1B. Common exon variants in the ACE2 gene in different populations. 
 
Variant ID Consequence 
A1/ 
N alleles 
ITA 
Freq 
ITA 
A1/ 
N alleles 
EUR 
Freq 
EUR 
A1/ 
N alleles 
EAS 
Freq 
EAS 
ITA 
Vs 
EUR 
ITA 
Vs 
EAS 
EUR 
Vs 
EAS 
rs2285666 c.439+4G>A 909/ 4408 0.206 
17240/ 
86164 0.200 
7336/ 
13387 0.548 0.331 P< 2.2e-16 P< 2.2e-16 
rs35803318 p.Val749Val 235/ 4422 0.053 
3935/ 
88946 0.044 0/13918 0.0 P=0.0058 P< 2.2e-16 P< 2.2e-16 
 
Total allele counts, carrier allele counts, and carrier frequencies are shown; only variants with MAF more than 5% were considered.  
A1: alleles carrying variants; Freq A1: frequency of A1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population 
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Table 2A. Burden of rare mutations in the TMPRSS2 gene in different 
populations. 
 
Population N alleles T1 Freq T1 ITA EUR EAS 
ITA 7968 30 0.0038 - P=0.039 P=3.6E-05 
EUR 129920 726 0.0056 P=0.039 - P=9.8E-16 
EAS 19979 25 0.0013 P=3.6E-05 P=9.8E-16 - 
 
Total allele counts, carrier allele counts, and carrier frequencies are shown; only deleterious 
variants with MAF less than 1% were considered in the burden analysis. The ‘deleterious’ set 
is defined by missense variations predicted to be possibly damaging by all the 5 algorithms 
used (LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar, and SIFT), and 
loss-of-function variants (nonsense, frameshift, and splicing variants affecting the 
donor/acceptor sites).  
T1: alleles carrying damaging variants; Freq T1: frequency of T1 allele; ITA: Italian population; 
EUR: European population; EAS: East Asian population 
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Table 2B. Common exon variants in the TMPRSS2 gene in different populations. 
 
Variant ID Consequence 
A1/ 
N alleles 
ITA 
Freq 
ITA 
A1/ 
N alleles 
EUR 
Freq 
EUR 
A1/ 
N alleles 
EAS 
Freq 
EAS 
ITA 
Vs 
EUR 
ITA 
Vs 
EAS 
EUR 
Vs 
EAS 
rs2298659 p.Gly259Gly 1388/ 7968 0.174 
28744/ 
122880 0.234 
5179/ 
19478 0.266 P< 2.2e-16 P< 2.2e-16 P< 2.2e-16 
rs17854725 p.Ile256Ile 4131/ 7968 0.518 
67712/ 
122814 0.551 
2544/ 
19604 0.130 P=1.16e-08 P< 2.2e-16 P< 2.2e-16 
rs12329760 p.Val160Met 1387/ 7968 0.174 
29831/ 
128604 0.232 
7651/ 
19934 0.384 P< 2.2e-16 P< 2.2e-16 P< 2.2e-16 
rs3787950 p.Thr75Thr 889/ 7968 0.112 
9864/ 
127666 0.077 
2905/ 
19600 0.148 P< 2.2e-16 P=1.39e-15 P< 2.2e-16 
 
Total allele counts, carrier allele counts, and carrier frequencies are shown; only variants with MAF more than 5% were considered.  
A1: alleles carrying variants; Freq A1: frequency of A1 allele; ITA: Italian population; EUR: European population; EAS: East Asian population.
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Table 2C. eQTL variants in the TMPRSS2 gene in different populations. 
 
Variant ID P GTEx 
NES 
GTEx 
Freq 
ITA 
Freq 
EUR 
Freq 
EAS 
ITA vs 
EUR 
ITA vs 
EAS 
EUR vs 
EAS 
rs463727 5.0e-10 0.12 0.44 0.46 0.0051 P=0.038 P<2.2e-16 P<2.2e-16 
rs2070788 8.9e-9 -0.11 0.55 0.53 0.66 P=0.003 P=4.7e-15 P<2.2e-16 
rs9974589 7.4e-9 -0.12 0.55 0.53 0.66 P=0.002 P=3.3e-15 P<2.2e-16 
rs34624090 9.2e-9 0.12 0.43 0.45 0.0051 P=0.005 P<2.2e-16 P<2.2e-16 
rs7364083 3.3e-9 -0.12 0.56 0.53 0.65 P=8.7e-05 P=1.9e-10 P<2.2e-16 
rs55964536 1.9e-9 0.12 0.46 0.49 0.0045 P=4.6e-04 P<2.2e-16 P<2.2e-16 
rs734056 1.3e-9 0.12 0.47 0.49 0.0051 P=0.030 P<2.2e-16 P<2.2e-16 
rs4290734 8.3e-10 0.12 0.47 0.49 0.0051 P=0.019 P<2.2e-16 P<2.2e-16 
rs34783969 3.9e-10 0.12 0.47 0.49 0.0051 P=0.027 P<2.2e-16 P<2.2e-16 
rs11702475 8.4e-10 0.12 0.47 0.49 0.0046 P=0.015 P<2.2e-16 P<2.2e-16 
rs35899679 7.8e-9 0.11 0.44 0.46 0.0051 P=0.004 P<2.2e-16 P<2.2e-16 
rs35041537 3.6e-9 0.12 0.44 0.47 0.0051 P=8.6e-04 P<2.2e-16 P<2.2e-16 
 
NES: normalized effect size; Freq: frequency of the minor allele; ITA: Italian population; EUR: European population; EAS: East Asian population 
 
 
 
 
